Niacin 500 mg by VitaCeutical Labs — Ingredients, Evidence & Safety

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

This product received a low score because the 500mg dose of niacin is more than 14 times the recommended maximum daily limit of 35mg.

Label Data

1 Tablet(s) Serving Size

100 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

500 mg (2500% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 14.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 500mg UL 35mg

Other Ingredients

Modified Cellulose Modified Cellulose Cellulose Stearic Acid Silica modified Cellulose Gum modified Cellulose Gum Magnesium Stearate Glycerin

Label Claims — Verification

❓ All Other

❓ Structure/Function

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) Gluten Free

Product Information

📋 Directions for Use

SUGGESTED USE: Take one tablet daily with food.

⚠️ Warnings & Precautions

KEEP OUT OF REACH OF CHILDREN.

🧪 Formulation Notes

Suitable for vegans.

CONTAINS NO artificial colors, flavors or preservatives; no wheat, gluten, milk, eggs, peanuts, tree nuts, soy, crustacean shellfish or fish.

Additional Information

223-100M

One of the B Vitamins, Niacin promotes healthy cholesterol levels and supports energy production. Our prolonged release niacin tablets use an advanced manufacturing technique which releases the nutrients slowly (over approximately 2-4 hours) promoting optimal assimilation.†

Prolonged Release

Supports Energy Production†

WE GUARANTEE OUR SUPPLEMENTS FOR POTENCY AND PURITY

DOUBLE VERIFIED GLUTEN FREE(TM)

Product Details

UPC / SKU 7 19985 22340 2

DSLD Entry Date 2012-02-23

Product Type Vitamin

Form Tablet or Pill

Brand VitaCeutical Labs

DSLD ID 6362

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →